Modelling trajectories and mechanisms of childhood hip dysplasia
The HIPSTAR project aims to identify and prevent hip dysplasia in children to reduce the risk of developing osteoarthritis in adulthood by studying growth patterns and causal factors.
Projectdetails
Introduction
With 40 million patients in Europe, osteoarthritis (OA) is the most common chronic and disabling disease. OA is incurable, and symptomatic treatments have limited effect. Therefore, prevention by identifying and targeting asymptomatic persons that develop a clear OA risk factor is sorely needed.
Risk Factors
Hip dysplasia is the strongest risk factor for hip OA. It is a condition of mechanical instability of the hip caused by insufficient coverage of the femoral head (ball) by a shallow or obliquely oriented acetabulum (socket). This results in high cartilage stress and subsequent hip OA.
Current Screening Practices
In Europe, we screen for developmental hip dysplasia in infants (prevalence 2%), enabling early treatment. However, we discovered that hip dysplasia can (further) develop during skeletal maturation and thus remains unrecognized. In 1100 Dutch 9-year-old children, we found a 6% and 26% prevalence of marked and mild hip dysplasia, respectively.
Developmental Insights
Hip dysplasia can be influenced until the stage where hip growth plates close at about age 13.
Proposed Research Program
I propose a novel research program (HIPSTAR) where I will uniquely unravel the mechanisms behind late childhood hip dysplasia in order to pave the way for devising preventive measures that reduce the prevalence of adult hip dysplasia and, thus, hip OA.
Research Methodology
In a birth cohort of 8000 children (followed from fetal life until adulthood), I will:
- Build a 5D growth model on how hip shape develops over time from age 2-18 years.
- Gain novel knowledge regarding causal factors of dysplastic growth and whether there are various phenotypes that have different underlying mechanisms.
- Study how and when dysplastic growth will already impact the integrity of the young adult joint and discover very early signs of joint aberration leading to OA.
Computational Analysis
Finally, in a computational model, I will test the influence of loading factors on dysplastic growth mechanistically and provide detailed information regarding the potential remedial options.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.499.373 |
Totale projectbegroting | € 2.499.373 |
Tijdlijn
Startdatum | 1-1-2023 |
Einddatum | 31-12-2027 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAMpenvoerder
- TECHNISCHE UNIVERSITEIT DELFT
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
reGeneRative bone Implant for the treatment of hip dysPlasiaGRIP aims to revolutionize hip dysplasia treatment with personalized, 3D-printed regenerative bone implants, enhancing integration and reducing invasiveness compared to current methods. | ERC Proof of... | € 150.000 | 2022 | Details |
In Silico Trials for Cartilage Regenerative Medicine ApplicationsThe INSTAnt CARMA project aims to develop and validate a multiscale in silico model for osteoarthritis to optimize drug and tissue-engineered therapies through virtual trials. | ERC Consolid... | € 2.212.385 | 2023 | Details |
Impact of the embryonic obesogenic environment on programming of cardiovascular diseases across the life courseOBESE-EMBRYO aims to improve cardiovascular health in future generations by targeting the embryonic obesogenic environment in overweight and obese parents-to-be through innovative, evidence-based interventions. | ERC Starting... | € 1.499.998 | 2025 | Details |
Development of an instrumented hammer to assess the stability of hip implant during surgery: assessment of the commercial feasibilityImpactor aims to develop a decision support system for assessing hip implant stability using an instrumented orthopedic hammer, enhancing surgical strategies and commercial potential in orthopedic surgery. | ERC Proof of... | € 150.000 | 2022 | Details |
Disruptive Therapies for the long-term relief of Osteoarthritis PainThe Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life. | ERC Consolid... | € 1.998.885 | 2023 | Details |
reGeneRative bone Implant for the treatment of hip dysPlasia
GRIP aims to revolutionize hip dysplasia treatment with personalized, 3D-printed regenerative bone implants, enhancing integration and reducing invasiveness compared to current methods.
In Silico Trials for Cartilage Regenerative Medicine Applications
The INSTAnt CARMA project aims to develop and validate a multiscale in silico model for osteoarthritis to optimize drug and tissue-engineered therapies through virtual trials.
Impact of the embryonic obesogenic environment on programming of cardiovascular diseases across the life course
OBESE-EMBRYO aims to improve cardiovascular health in future generations by targeting the embryonic obesogenic environment in overweight and obese parents-to-be through innovative, evidence-based interventions.
Development of an instrumented hammer to assess the stability of hip implant during surgery: assessment of the commercial feasibility
Impactor aims to develop a decision support system for assessing hip implant stability using an instrumented orthopedic hammer, enhancing surgical strategies and commercial potential in orthopedic surgery.
Disruptive Therapies for the long-term relief of Osteoarthritis Pain
The Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Bestrijding Artrose met Operatie RobotsDit project onderzoekt de haalbaarheid van het aanpassen van operatie robots voor de behandeling van artrose, met als doel precisie, kostenbesparing en gezondheidsvoordelen te realiseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Development of a Complete Triple Action Injectable Treatment for OsteoarthritisRelevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients. | EIC Transition | € 2.398.115 | 2022 | Details |
SmartForward 4 HealthHet project ontwikkelt het interactieve trainingssysteem SmartForward 4 Health om heuprevalidatie efficiënter, leuker en goedkoper te maken met behulp van digitale technologieën. | Mkb-innovati... | € 151.472 | 2021 | Details |
INTELLECTUALSDit project ontwikkelt een innovatief kraakbeen-op-een-chip model voor gepersonaliseerde behandelingen van osteoartritis. | 1.1 - Het ve... | € 479.529 | 2024 | Details |
SmartForward 4 HealthSmartForward 4 Health ontwikkelt een interactief trainingssysteem voor efficiëntere en leukere heuprevalidatie met digitale technologieën. | Mkb-innovati... | € 151.472 | 2021 | Details |
Bestrijding Artrose met Operatie Robots
Dit project onderzoekt de haalbaarheid van het aanpassen van operatie robots voor de behandeling van artrose, met als doel precisie, kostenbesparing en gezondheidsvoordelen te realiseren.
Development of a Complete Triple Action Injectable Treatment for Osteoarthritis
Relevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients.
SmartForward 4 Health
Het project ontwikkelt het interactieve trainingssysteem SmartForward 4 Health om heuprevalidatie efficiënter, leuker en goedkoper te maken met behulp van digitale technologieën.
INTELLECTUALS
Dit project ontwikkelt een innovatief kraakbeen-op-een-chip model voor gepersonaliseerde behandelingen van osteoartritis.
SmartForward 4 Health
SmartForward 4 Health ontwikkelt een interactief trainingssysteem voor efficiëntere en leukere heuprevalidatie met digitale technologieën.